CorVel Corp. (NASDAQ:CRVL – Get Free Report) VP Jennifer Yoss sold 1,999 shares of CorVel stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $61.02, for a total value of $121,978.98. Following the transaction, the vice president owned 2,173 shares of the company’s stock, valued at $132,596.46. The trade was a 47.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
CorVel Trading Down 2.7%
Shares of NASDAQ CRVL traded down $1.65 during trading on Wednesday, reaching $59.40. 246,923 shares of the company traded hands, compared to its average volume of 183,009. The firm’s fifty day simple moving average is $56.43 and its 200 day simple moving average is $61.35. The stock has a market cap of $3.01 billion, a P/E ratio of 27.76 and a beta of 0.98. CorVel Corp. has a 12-month low of $44.83 and a 12-month high of $113.64.
CorVel (NASDAQ:CRVL – Get Free Report) last released its quarterly earnings data on Tuesday, May 19th. The business services provider reported $0.61 earnings per share for the quarter. The business had revenue of $248.55 million during the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.51%.
Institutional Investors Weigh In On CorVel
Analysts Set New Price Targets
Separately, Weiss Ratings cut CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.
View Our Latest Stock Report on CRVL
CorVel Company Profile
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
Further Reading
- Five stocks we like better than CorVel
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
